Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

740
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
740
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Cancer Therapies02:49

Cancer Therapies

8.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Cancer Vaccines01:30

Cancer Vaccines

562
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
562

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Challenges and strategies in the management of ER/PgR Low-expression breast cancer: exploring fundamentals, clinical insights, and treatment approaches.

Frontiers in oncology·2026
Same author

Editorial: Integrating nutrition in cancer therapy: approaches to improve patient outcomes and survival.

Frontiers in oncology·2026
Same author

Adjuvant endocrine therapy in estrogen-low breast cancer in the era of CDKI: are we at another uncertain crossroads?

Frontiers in oncology·2026
Same author

Observational Study on the Effectiveness of L-Arginine Plus Vitamin C in the Management of Cancer-related Fatigue.

In vivo (Athens, Greece)·2026
Same author

Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.

Current oncology (Toronto, Ont.)·2026
Same author

Why pay more for robot in breast surgery: literature review and analysis of costs.

Gland surgery·2026

Related Experiment Video

Updated: Oct 16, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Immunotherapeutic Advances for NSCLC.

Marco Massafra1, Maria Ilenia Passalacqua1, Vittorio Gebbia2,3

  • 1Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.

Biologics : Targets & Therapy
|October 22, 2021
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment. Research is exploring new biomarkers beyond PD-L1 to predict response and overcome resistance to these immunotherapies.

Keywords:
anti-PD-1/PD-L1 antibodiesimmunotherapynon-small cell lung cancer

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

Related Experiment Videos

Last Updated: Oct 16, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.2K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

Area of Science:

  • Oncology
  • Immunology
  • Pulmonology

Background:

  • Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have revolutionized non-small cell lung cancer (NSCLC) treatment.
  • While effective, ICIs show limited response rates and acquired resistance in many NSCLC patients.
  • PD-L1 expression is used for patient selection, but its predictive value is debated, necessitating better biomarkers.

Purpose of the Study:

  • To provide an overview of recent advances in NSCLC immunotherapy.
  • To discuss updated results of ICI studies in various NSCLC settings and treatment lines.
  • To highlight emerging predictive biomarkers and strategies to overcome ICI resistance.

Main Methods:

  • Review of recent clinical studies and literature on NSCLC immunotherapy.
  • Analysis of data on ICI efficacy in different disease stages and treatment lines.
  • Exploration of novel predictive biomarkers and resistance mechanisms.

Main Results:

  • ICIs demonstrate significant efficacy in NSCLC, including early-stage and locally advanced disease.
  • Emerging biomarkers related to tumor signaling, metabolism, and microenvironment show promise for patient selection.
  • Acquired resistance to ICIs is a significant challenge, requiring novel therapeutic approaches.

Conclusions:

  • Immunotherapy with ICIs has significantly improved NSCLC treatment outcomes.
  • Optimizing patient selection through novel biomarkers is crucial for enhancing ICI efficacy.
  • Developing strategies to overcome or delay ICI resistance is essential for long-term patient benefit.